No Data
No Data
International Medicine (000516.SZ): Net profit for the first quarter - $105 million
On April 25, Ge Longhui (000516.SZ) released its report for the first quarter of 2024, achieving operating income of 1,173 billion yuan, an increase of 10.75% over the previous year; net profit attributable to shareholders of listed companies - 105 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 898.496 million yuan, basic earnings per share - 0.0464 yuan.
Published 2 articles in a row in the top international medical journal “The Lancet”, a team from Jiangsu is expected to rewrite the international treatment guidelines for coronary heart disease
Recently, two groundbreaking research results carried out by Professor Chen Shaoliang's team from the Department of Cardiovascular Medicine at Nanjing First Hospital were published in the official issue of the top international medical journal “The Lancet”. These two clinical practices from China have provided China's solutions for interventional treatment of coronary heart disease in the world, expanded the international influence of coronary heart disease clinical research in China, and will fill the gaps in Chinese and Western cardiovascular treatment guidelines. The reporter learned that both studies revolved around a serious coronary heart disease — acute coronary syndrome.
International Medicine (000516) In-depth Research Report: The time is right for a regional comprehensive medical service leader to take off
Through transformation, a high-level, research-based, and multi-level comprehensive medical service platform has taken shape. Adhering to the tenet of “protecting the immeasurable value”, with the innovative business model of “comprehensive medical+special specialties”, the infrastructure of international medicine has now become a whole life
International Medicine (000516.SZ): Chairman, Vice Chairman and all executives increased their holdings by a total of 537,900 shares
Gelonghui, Feb. 2 | International Medicine (000516.SZ) announced that the company received notifications from the chairman, vice chairman and all senior management of the company to learn that the company's chairman, Ms. Shi Jin, Vice Chairman, Ms. Wang Aiping, Director and President Mr. Liu Ruixuan, Director and Vice President, Mr. Sun Wenguo, Vice President and Board Secretary, Mr. Wang Yu, Vice President, Mr. Sun Yikuan, Vice President, and Ms. Wang Yaxing increased the company's shares by centralized bidding through the Shenzhen Stock Exchange trading system from January 31 to February 2, 2024, accounting for Total share capital of the company 2,260
International Medicine (000516): High revenue growth in 2023Q4, steady profits, and 2024 is expected to usher in a profit inflection point
Key Investment Highlights On January 30, the company released its 2023 performance forecast: estimated revenue of 4.61585-4.658.5 billion yuan in 2023 (year-on-year increase of 70.27%-71.74%), net return to mother
International Medicine (000516): Operating losses narrowed month-on-month in the fourth quarter, revenue climbed and business trends improved in 23 years
Key investment events: The company announced that in 2023, the company achieved operating income of 4.616 to 4.656 billion yuan, and net revenue of 4.45 to 4.48 billion yuan. The company expects to achieve a net profit loss of 2.8-3 to the mother.
No Data